论文部分内容阅读
目的:探讨FOLFOX方案联合西妥昔单抗治疗转移性结直肠癌的近期临床疗效及安全性。方法:选择2009年2月~2011年2月本院诊治的42例转移性结直肠癌患者为研究对象,采用随机数字表法将其随机分入对照组与观察组,其中对照组20例,观察组22例。对照组患者接受FOLFOX方案治疗,每2周重复1次,治疗3周期;观察组患者给予FOLFOX方案联合西妥昔单抗治疗。比较两组的近期疗效及毒副反应。结果:观察组的客观缓解率和疾病控制率均显著高于对照组,差别具有统计学意义(P<0.05);骨髓抑制、消化道反应、神经毒性是两组常见的毒副反应,两组患者骨髓抑制、消化道反应、神经毒性、脱发及肝功能损害发生率无显著差别(P>0.05),观察组痤疮样皮疹的发生率显著高于对照组(36.4%vs 0,P<0.05)。结论:西妥昔单抗联合FOLFOX方案可提高转移性结直肠癌患者的近期疗效,毒副反应可耐受。
Objective: To investigate the short-term clinical efficacy and safety of FOLFOX combined with cetuximab in the treatment of metastatic colorectal cancer. Methods: Forty-two patients with metastatic colorectal cancer diagnosed and treated in our hospital from February 2009 to February 2011 were enrolled in this study. They were randomly divided into control group and observation group using random number table. Among them, 20 cases in control group, Observation group of 22 cases. Patients in the control group were treated with FOLFOX regimen and repeated once every 2 weeks for 3 cycles. Patients in the observation group were given FOLFOX regimen combined with cetuximab. The two groups were compared the short-term efficacy and toxicity. Results: The objective remission rate and disease control rate in the observation group were significantly higher than those in the control group (P <0.05). Myelosuppression, digestive tract reaction and neurotoxicity were common toxicities in both groups. Two groups There was no significant difference in the incidence of myelosuppression, gastrointestinal reaction, neurotoxicity, hair loss and liver damage (P> 0.05). The incidence of acne-like rash in the observation group was significantly higher than that in the control group (36.4% vs 0, P <0.05) . Conclusion: Cetuximab combined with FOLFOX regimen can improve the short-term curative effect of patients with metastatic colorectal cancer. Toxicity and side effects can be tolerated.